"With 35 urologists, Urology Associates is the leader of urological care in Tennessee. We provide comprehensive and compassionate urological care to men and women."

During the past decade, Urology Associates conducted 30 clinical trials. In the 10-year time frame, 30 clinical trials started and 15 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 8 clinical trials were completed. i.e. 38.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Urology Associates" #1 sponsor was "Janssen Research & Development, LLC" with 10 trials, followed by "Dendreon" with 7 trials sponsored, "GP-Pharm" with 3 trials sponsored, "UroGen Pharma Ltd." with 3 trials sponsored and "Abbott" with 3 trials sponsored. Other sponsors include 21 different institutions and companies that sponsored additional 27 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Urology Associates" #1 collaborator was "Astellas Pharma Inc" with 2 trials as a collaborator, "Daré Bioscience, Inc." with 1 trials as a collaborator, "Foundation Medicine" with 1 trials as a collaborator, "Helsinn Healthcare SA" with 1 trials as a collaborator and "Hormos Medical" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Urology Associates" are "Prostate Cancer" (14 trials), "Urinary Bladder Neoplasms" (6 trials), "Bladder Cancer" (5 trials), "Urothelial Carcinoma" (5 trials) and "Prostate Cancer Metastatic" (3 trials). Many other conditions were trialed in "Urology Associates" in a lesser frequency.

Most popular intervention types in "Urology Associates" are "Drug" (38 trials), "Biological" (13 trials), "Other" (3 trials), "Diagnostic Test" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Prednisone" (4 trials), "TAR-200" (4 trials), "sipuleucel-T" (4 trials) and "Cetrelimab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Urology Associates" are 32 trials for "Male" genders, 17 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Urology Associates". undefined are not yet recruiting, 12 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 20 completed trials in Urology Associates, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Urology Associates, 9 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".

Urology Associates has several departments that took part in Clinical trials: "Urology Associates Clinical Research" - 3 trials